1. Immune Reconstitution in MS:

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Evolving Therapeutic Landscape in MS

4. Barts-MS T2T-NEDA Algorithm

5. Defining IRT and Maintenance Therapy

6. Maintenance Therapies vs IRTs

7. Maintenance Therapies vs IRTs: Attributes

8. Treatment Burden of DMTs in MS

9. DMT Adherence in MS

10. Monitoring Burden With DMTs in MS

11. Daclizumab

12. Immunosuppression

13. Continuous vs Short-Term Immunosuppression

14. Immunosuppression Risks Over Time

15. Fingolimod

16. Natalizumab

17. Alemtuzumab

18. Alemtuzumab Risks Identified in Clinical Trials

19. Cladribine

20. De-Risking Immunosuppression

21. Maintenance Therapies vs IRTs: Vaccines and Pregnancy

22. Case Study 1

23. Vaccinations

24. Pregnancy

25. Pregnancy (cont)

26. Pregnancy (cont)

27. Defining an MS Cure?

28. 10-Year Durable Efficacy of Alemtuzumab CAMMS223

29. CIS Conversion to MS With Cladribine

30. Case Study 2

31. NEDA Rates in Phase 3 Trials

32. Flipping the Pyramid in MS

33. A New Classification of DMTs for RMS

34. Personalizing Therapy

35. Conclusions

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)

39. Abbreviations (cont)